 Dyadic International Inc NASDAQ: DYAI has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using Dyadics proprietary C1-cell protein production platform. 